

to § 225.25(b)(1) of the Board's Regulation Y.

Board of Governors of the Federal Reserve System, March 22, 1995.

**Jennifer J. Johnson,**

*Deputy Secretary of the Board.*

[FR Doc. 95-7521 Filed 3-27-95; 8:45 am]

BILLING CODE 6210-01-F

**Otis Truman Arnold, et al.; Change in Bank Control Notices; Acquisitions of Shares of Banks or Bank Holding Companies**

The notificants listed below have applied under the Change in Bank Control Act (12 U.S.C. 1817(j)) and § 225.41 of the Board's Regulation Y (12 CFR 225.41) to acquire a bank or bank holding company. The factors that are considered in acting on the notices are set forth in paragraph 7 of the Act (12 U.S.C. 1817(j)(7)).

The notices are available for immediate inspection at the Federal Reserve Bank indicated. Once the notices have been accepted for processing, they will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing to the Reserve Bank indicated for that notice or to the offices of the Board of Governors. Comments must be received not later than April 11, 1995.

**A. Federal Reserve Bank of Dallas** (Genie D. Short, Vice President) 2200 North Pearl Street, Dallas, Texas 75201-2272:

1. *Otis Truman and Anita Ray Arnold*, both of Texarkana, Texas; to acquire a total of 49.1 percent of the voting shares of New Boston Bancshares, Inc., New Boston, Texas, and thereby indirectly acquire First National Bank of New Boston, New Boston, Texas.

**B. Federal Reserve Bank of San Francisco** (Kenneth R. Binning, Director, Bank Holding Company) 101 Market Street, San Francisco, California 94105:

1. *James Lester Ryan*, Orinda, California; to acquire an additional 2.32 percent, for a total of 10.65 percent, of the voting shares of BWC Corp., Walnut Creek, California, and thereby indirectly acquire Bank of Walnut Creek, Walnut Creek, California.

Board of Governors of the Federal Reserve System, March 22, 1995.

**Jennifer J. Johnson,**

*Deputy Secretary of the Board.*

[FR Doc. 95-7519 Filed 3-27-95; 8:45 am]

BILLING CODE 6210-01-F

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Centers for Disease Control and Prevention**

**Board of Scientific Counselors, National Institute for Occupational Safety and Health; Meeting**

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC), announces the following committee meeting.

*Name:* Board of Scientific Counselors, National Institute for Occupational Safety and Health (BSC, NIOSH).

*Time and Date:* 10 a.m.-5 p.m., April 12, 1995.

*Place:* The Washington Court Hotel, Ash Room, 525 New Jersey Avenue, NW, Washington, DC 20001

*Status:* Closed 10 a.m.-12 noon; Open 1 p.m.-5 p.m.

*Purpose:* The Board reviews research activities to provide guidance on the quality, timeliness, and efficacy of the Institute's programs.

*Matters To Be Discussed:* The agenda will include personnel and organizational issues relating to the reorganization of NIOSH. The meeting will convene in closed session from 10 a.m. to 12 noon to discuss subject matter relating solely to the internal personnel rules and practices of NIOSH. This portion of the meeting will be closed to the public in accordance with the provisions set forth in section 552b(c)(2), title 5 U.S.C., and the Determination of the Associate Director for Management and Operations, CDC, pursuant to Pub. L. 92-463. The open portion of the meeting will include a report from the Director of NIOSH, a toxicology report, an extramural report, and future activities of the Board.

Agenda items are subject to change as priorities dictate.

*Contact Person for More Information:* Richard A. Lemen, Ph.D., Executive Secretary, BSC, NIOSH, and Deputy Director, NIOSH, CDC, 1600 Clifton Road NE., Mailstop D-35, Atlanta, Georgia 30333, telephone 404/639-3773.

Dated: March 22, 1995.

**Jack Jackson,**

*Associate Director for Management and Operations, Centers for Disease Control and Prevention (CDC).*

[FR Doc. 95-7579 Filed 3-27-95; 8:45 am]

BILLING CODE 4163-19-M

**Food and Drug Administration**

[Docket No. 94D-0407]

**Miscellaneous Compliance Policy Guides; Revocation**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing the revocation of two compliance policy guides (CPG's) because they are outdated. This action is being taken to ensure that FDA's CPG's are accurate and current.

**DATES:** Effective March 28, 1995.

**FOR FURTHER INFORMATION CONTACT:** Judith A. Gushee, Center for Veterinary Medicine (HFV-236), Food and Drug Administration, 7500 Standish Place, Rockville, MD 20855, 301-594-1785.

**SUPPLEMENTARY INFORMATION:** FDA is revoking the following CPG's because they are outdated:

(1) CPG 7126.06 "State Analysis of Animal Feed for Protein, Fat, and Fiber Content," and

(2) CPG 7126.14 "Protein in Animal Feeds."

These CPG's were intended to assist the States in enforcing their requirements for guaranteed analysis labeling claims when their regulatory authority was insufficient. However, State regulatory authority is sufficient, and the States have not required use of these CPG's for a number of years. Furthermore, if FDA regulatory action is required, the agency has ample authority. Therefore, FDA is revoking CPG's 7126.06 and 7126.14 because they are outdated.

Dated: March 13, 1995.

**Gary Dykstra,**

*Acting Associate Commissioner for Regulatory Affairs.*

[FR Doc. 95-7615 Filed 3-27-95; 8:45 am]

BILLING CODE 4160-01-F

[Docket No. 94D-0356]

**Protocol Development for Clinical Effectiveness and Target Animal Safety Trials; Availability of Guideline**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing the availability of the guideline entitled, "Protocol Development Guideline for Clinical Effectiveness and Target Animal Safety Trials" prepared by the Center for Veterinary Medicine (CVM). This guideline describes a suggested systematic approach to be followed when designing and reporting effectiveness and target animal safety studies that are conducted to provide data to support animal drug approvals.

**DATES:** Written comments may be submitted at any time.

**ADDRESSES:** Submit written requests for single copies of the guideline entitled, "Protocol Development Guideline for Clinical Effectiveness and Target Animal Safety Trials" to the Communications and Education Branch (HFV-12), Center for Veterinary Medicine, Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-594-1755. Send two self-addressed adhesive labels to assist that office in processing your requests. Submit written comments on the guideline to the Dockets Management Branch (HFA-305), Food and Drug Administration, rm. 1-23, 12420 Parklawn Dr., Rockville, MD 20857. Requests and comments should be identified with the docket number found in brackets in the heading of this document. A copy of the guideline and received comments are available for public examination in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday.

**FOR FURTHER INFORMATION CONTACT:** Larry Ventura, Center for Veterinary Medicine (HFV-130), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-594-1647.

**SUPPLEMENTARY INFORMATION:** FDA is announcing the availability of the guideline entitled, "Protocol Development Guideline for Clinical Effectiveness and Target Animal Safety Trials" prepared by CVM. The guideline is intended to be used by clinical investigators, study monitors, and sponsors, when designing investigations of effectiveness and target animal safety for animal drug approval and may be used when submitting the final reports of these trials. This guideline was written in response to a request by the animal health industry for guidance on facilitating protocol development and expediting CVM's review of the submitted protocols, and it should help sponsors to include all essential components of the study in the protocol. More uniform reports should allow a systematic, orderly review of the data by CVM. The goals of the protocol development guideline are to:

1. Suggest a uniform system for writing study protocols,
2. Provide a reference of essential items that should be considered for inclusion in a study protocol,
3. Facilitate the development of complete study protocol(s) by the author(s),
4. Design more user friendly protocols for investigator(s),
5. Enable FDA reviewers to evaluate study protocols more quickly and convey their comments in terms more easily understood by the sponsor, and

6. Reduce the number of essential revisions of study protocols.

The guideline offers a complete outline of the components necessary for a well-designed study so that CVM and industry have a common reference point. This uniform approach will facilitate the drafting of study reports by the sponsor and their subsequent review by CVM. The contents of this guideline are neither all inclusive nor will all items listed be applicable to all study protocols. It is the responsibility of the sponsor to ensure that the essential components of a study are included in their protocol. Guidelines state procedures or practices that may be useful to the persons to whom they are directed, but are not legal requirements. A person may follow the guideline or may choose to follow alternate procedures or practices. If a person chooses to use alternate procedures or practices, that person may wish to discuss the matter further with the agency to prevent an expenditure of money and effort on activities that may later be determined to be unacceptable to FDA.

Guidelines are generally issued under §§ 10.85(a) and 10.90(b) (21 CFR 10.85(a) and 10.90(b)). The agency is now in the process of revising §§ 10.85(a) and 10.90(b). Therefore, this guideline is not being issued under the authority of §§ 10.85(a) and 10.90(b). A guideline does not bind the agency, and it does not create or confer any rights, privileges, or benefits for or on any person. When a guideline states a requirement imposed by statute or regulation, however, the requirement is law and its force and effect are not changed in any way by virtue of its inclusion in the guideline.

Interested persons may, at any time, submit written comments on the guideline to the Dockets Management Branch (address above). FDA will consider these comments in determining whether further amendments to, or revisions of, the document are warranted. Two copies of any comments should be submitted, except that individuals may submit one copy, identified with the docket number found in brackets in the heading of this document. The guideline and received comments may be seen in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday, at the Dockets Management Branch.

Dated: March 16, 1995.

**William B. Schultz,**

*Deputy Commissioner for Policy.*

[FR Doc. 95-7513 Filed 3-27-95; 8:45 am]

BILLING CODE 4160-01-F

### **Industry and Consumer Exchange Meeting Concerning FDA and APHIS Activities on a Potential Agreement With the European Union Related to Human and Animal Drug and Biological Product Information; Notice of Public Meeting**

**AGENCIES:** Food and Drug Administration, HHS.

**ACTION:** Notice of public meeting.

**SUMMARY:** The Food and Drug Administration (FDA) and Animal and Plant Health Inspection Service (APHIS) are cosponsoring a public meeting with all persons interested in a potential agreement with the European Union that would facilitate the harmonization of good manufacturing practices (GMP's) and quality controls for human and animal drug and biological products and associated compliance and enforcement activities, and provide for the exchange and use of such information by the respective regulatory authorities. Such an agreement would enhance the goals of harmonizing the monitoring and enforcement standards of the GMP's and would facilitate international trade.

**DATES:** The industry and consumer exchange meeting will be held on Friday, March 31, 1995, 9 a.m. to 12 m.

**ADDRESSES:** The industry and consumer exchange meeting will be held at the Hubert H. Humphrey Bldg., Humphrey Auditorium, 200 Independence Ave. SW., Washington, DC.

**FOR FURTHER INFORMATION CONTACT:** Walter M. Batts, Office of Health Affairs (HFY-50), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-443-4480 (Fax 301-443-0235).

Those persons interested in attending this meeting should Fax their registration, including name, firm, or organization name, address, and telephone number to Nathaniel L. Geary, Office of External Affairs, Food and Drug Administration (301-443-5153) or telephone 301-443-6776. There is no registration fee, but advance registration is requested. Additionally, if there are any individuals that wish to make a presentation at this meeting, advance notice is required.

**SUPPLEMENTARY INFORMATION:** The purpose of the public meeting is to provide information concerning FDA and APHIS activities with the European Union related to human and animal drug and biological product GMP's and quality controls, as well as to provide an opportunity to hear and address concerns from persons involved in these industries and persons representing consumer and other interests.